MISONIX, Inc. (NASDAQ:MSON) is reporting first quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.3 per share.
For the full year, analysts predict revenues of $ 78.50 million, while looking forward to loss of $ 0.79 per share.
The Company Outlook
Revenue for 1Q21 are expected in a range of $ 17.70 million ~ $ 17.70 million
Click Here For More Historical Outlooks Of MISONIX, Inc.
Previous Quarter Performance
MISONIX, Inc. unveiled loss for the fourth quarter of $ 0.50 per share, from the revenue of $ 13.71 million. The quarterly revenues grew 40.62 percent compared with the same quarter last year. Street analysts expected MISONIX, Inc. to report loss of $ 0.48 per share on revenue of $ 9.51 million for the fourth quarter. The bottom line results missed street analysts by $ 0.02 or 4.17 percent, at the same time, top line results outshined analysts by $ 4.20 million or 44.16 percent.
Stock Performance
Shares of MISONIX, Inc. traded low $ -0.26 or -2.24 percent on Wednesday, reaching $ 11.35 with volume of 16.60 thousand shares. MISONIX, Inc. has traded high as $ 11.74 and has cracked $ 11.23 on the downward trend
The closing price of $ 11.35, representing a 73.03 % increase from the 52 week low of $ 6.71 and a 47.7 % decrease over the 52 week high of $ 22.20.
The company has a market capital of $ 197.20 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
MISONIX, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.misonix.com
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgical applications.
